Here we go…..6 Sep 2023 07:01
RNS Number : 4654L Sareum Holdings PLC 06 September 2023
Sareum Holdings PLC ("Sareum" or the "Company")
Director's Dealing
Cambridge, UK, 05 September 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces that Dr Stephen Parker, Non-Executive
Chairman, purchased 12,500 ordinary shares of 0.0125 pence each in the Company ("Ordinary Shares") at an average price of 80 pence per share on 5 September 2023.
In addition, persons connected with Dr Parker are interested in a further 25,680 Ordinary Shares in the Company, over which Ordinary Shares Dr
Parker has voting rights discretion.
Therefore, following the transaction, Dr Parker has direct and indirect interests in an aggregate 116,160 Ordinary Shares in the Company, representing approximately 0.16 per cent. of the Company's currently issued share capital.
The notification below, which has been made in accordance with the requirements of the Market Abuse Regulation, provides further details.
PDMR Notification Form: 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Stephen Parker 2 Reason for the notification a) Position/status Non-Executive Chairman b) Initial notification/amendment Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Sareum Holdings plc b) LEI 213800PKERN2DY8FFM72 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Ordinary shares of 0.0125 pence each in the share capital of Sareum Holdings plc